Envestnet Asset Management Inc. Purchases 157,605 Shares of Sanofi $SNY

Envestnet Asset Management Inc. lifted its holdings in shares of Sanofi (NASDAQ:SNY) by 4.8% in the second quarter, HoldingsChannel reports. The institutional investor owned 3,434,999 shares of the company’s stock after buying an additional 157,605 shares during the period. Envestnet Asset Management Inc.’s holdings in Sanofi were worth $165,945,000 as of its most recent SEC filing.

A number of other large investors also recently modified their holdings of SNY. Brighton Jones LLC boosted its stake in shares of Sanofi by 52.6% during the 4th quarter. Brighton Jones LLC now owns 5,420 shares of the company’s stock worth $261,000 after buying an additional 1,869 shares during the last quarter. GAMMA Investing LLC boosted its stake in shares of Sanofi by 58.7% during the 1st quarter. GAMMA Investing LLC now owns 6,057 shares of the company’s stock worth $336,000 after buying an additional 2,241 shares during the last quarter. Cambridge Investment Research Advisors Inc. boosted its stake in shares of Sanofi by 1.0% during the 1st quarter. Cambridge Investment Research Advisors Inc. now owns 33,328 shares of the company’s stock worth $1,848,000 after buying an additional 318 shares during the last quarter. Oppenheimer & Co. Inc. boosted its stake in shares of Sanofi by 3.6% during the 1st quarter. Oppenheimer & Co. Inc. now owns 8,640 shares of the company’s stock worth $479,000 after buying an additional 298 shares during the last quarter. Finally, Bessemer Group Inc. boosted its stake in shares of Sanofi by 570.6% during the 1st quarter. Bessemer Group Inc. now owns 4,339 shares of the company’s stock worth $240,000 after buying an additional 3,692 shares during the last quarter. 14.04% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

SNY has been the subject of a number of recent research reports. JPMorgan Chase & Co. upgraded shares of Sanofi from a “neutral” rating to an “overweight” rating in a research note on Friday, August 8th. Barclays reiterated an “overweight” rating on shares of Sanofi in a research note on Wednesday, July 2nd. Deutsche Bank Aktiengesellschaft upgraded shares of Sanofi from a “hold” rating to a “buy” rating in a research note on Tuesday, September 2nd. Morgan Stanley upgraded shares of Sanofi from an “equal weight” rating to an “overweight” rating and raised their target price for the company from $56.00 to $58.00 in a research note on Monday, September 8th. Finally, Weiss Ratings reiterated a “hold (c)” rating on shares of Sanofi in a research note on Wednesday, October 8th. Two research analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating and two have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Buy” and an average target price of $62.67.

Sanofi Trading Down 0.7%

Shares of SNY stock opened at $51.06 on Wednesday. The firm has a 50 day moving average price of $48.70 and a two-hundred day moving average price of $49.55. The company has a quick ratio of 0.94, a current ratio of 1.06 and a debt-to-equity ratio of 0.16. The company has a market capitalization of $125.38 billion, a PE ratio of 11.96, a price-to-earnings-growth ratio of 1.41 and a beta of 0.51. Sanofi has a 12-month low of $44.62 and a 12-month high of $60.12.

Sanofi (NASDAQ:SNY) last issued its quarterly earnings data on Friday, October 24th. The company reported $1.70 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.60 by $0.10. The firm had revenue of $14.53 billion during the quarter, compared to the consensus estimate of $12.62 billion. Sanofi had a net margin of 21.96% and a return on equity of 12.70%. The business’s revenue for the quarter was down 7.5% compared to the same quarter last year. During the same period last year, the business posted $2.25 earnings per share. As a group, analysts predict that Sanofi will post 4.36 earnings per share for the current year.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.